ACR Presentations Highlight Utility of Crescendo's Vectra DA Test beyond Disease Monitoring | GenomeWeb

Researchers presenting data on Crescendo Bioscience's Vectra DA test at the American College of Rheumatology annual meeting late last month shared a number of studies supporting the potential of the test not just for disease monitoring, but also to predict patients' risk of joint damage.

Crescendo's Vectra DA is a blood-based test that measures the levels of 12 proteins associated with rheumatoid arthritis, yielding a test score between one and 100 that is intended to help doctors determine whether a patient has high, moderate, or low RA disease activity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.